Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00762 ...
Drug Name Irinotecan
Molecular Weight 586.678
Molecular Formula C33H38N4O6
CAS Number 97682-44-5
SMILES CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
External Links
DRUGBANK DB00762
PubChem Compound 60838
PDR 1017
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 3.2 - 3.2 - DRUGBANK
Melting Point 222.5 ℃ 222-223 ℃ DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Reference
AUC 10200.0 ng.h/ml 10200.0 ng.h/ml tumor; DRUGBANK
AUC 20604.0 ng.h/ml 20604.0 ng.h/ml tumor; DRUGBANK
C Max 1660.0 ng/ml 1660.0 ng/ml tumor; DRUGBANK
C Max 3392.0 ng/ml 3392.0 ng/ml tumor; DRUGBANK
C Max 1700.0 ng/ml 1.7±0.8 mcg/ml intravenous infusion, IV in drop; solid tumors; The Pharmacological Basis of Therapeutics
C Max 26.0 ng/ml 26±12 ng/ml intravenous infusion, IV in drop; Active metabolite; solid tumors; The Pharmacological Basis of Therapeutics
T Max 0.50 h 0.5 h intravenous infusion, IV in drop; solid tumors; The Pharmacological Basis of Therapeutics
T Max 1.0 h ≤1 h intravenous infusion, IV in drop; Active metabolite; solid tumors; The Pharmacological Basis of Therapeutics
Clearance 13.3 L/h/m2 13.3 L/h/m2 tumor; patients; DRUGBANK
Clearance 13.9 L/h/m2 13.9 L/h/m2 tumor; patients; DRUGBANK
Clearance 14.8 L/h/m2 14.8±4 L/h/m2 The Pharmacological Basis of Therapeutics
Clearance 0.42 L/h/kg 7 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 110.0 L/m2 110.0 L/m2 tumor; patients; DRUGBANK
Volume of Distribution 234.0 L/m2 234.0 L/m2 tumor; patients; DRUGBANK
Volume of Distribution 150.0 L/m2 150±49 L/m2 The Pharmacological Basis of Therapeutics
Volume of Distribution 3.5 L/kg 3.5 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 9.0 h ~6-12 h DRUGBANK
Half-life 15.0 h 10-20 h elimination half-life; DRUGBANK
Half-life 10.8 h 10.8±0.5 h The Pharmacological Basis of Therapeutics
Half-life 10.4 h 10.4±3.1 h Male, men;  Female, women; patients; malignant solid tumors; The Pharmacological Basis of Therapeutics
Half-life 9.0 h 9 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 16.7 % 16.7±1 % Urinary excretion; malignant solid tumors; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 49.0 % 30-68 % DRUGBANK
Protein Binding 49.0 % 30-68 % malignant solid tumors; human, homo sapiens; The Pharmacological Basis of Therapeutics
Protein Binding 95.0 % 95 % Active metabolite; malignant solid tumors; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Frequency Brand Name Component Reference
Max dose for adolescents 16.6666666666667 mg/m2/day 350 mg/m2/3 weeks intravenous injection, IV Camptosar irinotecan hydrochloride PDR
Max dose for adolescents 300.0 mg/m2 300 mg/m2 Camptosar irinotecan hydrochloride PDR
Max dose for adolescents 17.8571428571429 mg/m2/day 125 mg/m2/week intravenous injection, IV Camptosar irinotecan hydrochloride PDR
Max dose for adolescents 12.8571428571429 mg/m2/day 180 mg/m2/2 weeks intravenous injection, IV Camptosar irinotecan hydrochloride PDR
Max dose for adolescents 17.8571428571429 mg/m2/day 125 mg/m2/week intravenous injection, IV Camptosar irinotecan hydrochloride PDR
Max dose for geriatric 350.0 mg/m2/dose 350 mg/m2/dose intravenous injection, IV q3w Camptosar irinotecan hydrochloride PDR
Max dose for geriatric 125.0 mg/m2/week 125 mg/m2/week intravenous injection, IV Camptosar irinotecan hydrochloride PDR
Max dose for geriatric 180.0 mg/m2/dose 180 mg/m2/dose intravenous injection, IV qw Camptosar irinotecan hydrochloride PDR
Max dose for geriatric 125.0 mg/m2/week 125 mg/m2/week intravenous injection, IV Camptosar irinotecan hydrochloride PDR
Max dose for adults 70.0 mg/m2 70 mg/m2 intravenous injection, IV q2w Onivyde irinotecan liposome PDR
Max dose for geriatric 70.0 mg/m2 70 mg/m2 intravenous injection, IV q2w Onivyde irinotecan liposome PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1